# MORE implementation

Source: https://www.keypedia.com/records/uk_mhra_guidance/uk-mhra/496764ca-37ca-4e2e-a1e6-8744ab104703
Type: Guidance
Published: May 15, 2025
Updated: June 9, 2025

> The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced significant updates to its operational procedures following the enactment of the Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024. This regulatory update is designed to enhance the safety oversight of medical devices currently available on the Great Britain market. By refining how data is collected and analyzed, the MHRA aims to identify trends, patterns, and signals that could indicate new risks or safety concerns more effectively than previous methods allowed. While this specific guidance does not name a single company or cite specific inspection dates, it establishes a new compliance baseline for all medical device manufacturers operating within the region. The primary focus of the framework is to shift toward a more proactive surveillance model. Under these updated requirements, manufacturers and healthcare stakeholders are expected to implement more rigorous data management practices. This includes adhering to newly defined documentation standards that support the reporting of post-market performance. The required actions for the healthcare system involve the immediate integration of these updated data requirements into their existing safety protocols. By ensuring that potential hazards are flagged early, the MHRA and the broader healthcare network can take swifter action to protect patient health. These changes represent a critical evolution in the UK's approach to medical device regulation, ensuring that safety monitoring remains robust throughout the entire lifecycle of a product.

---

## Content

Following the passing of the Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 , the MHRA has updated its processes and procedures to ensure that trends, patterns or signals that may reveal new risks or safety concerns are identified more efficiently. This will allow both the MHRA and the whole healthcare system to better protect patients. For documentation to support these changes, see Documentation for implementation of data requirements under the new Post-Marketing Surveillance regulations

## Attachments

- [GB MIR and FSCA schema implementation guide](/government/publications/more-implementation/gb-mir-and-fsca-schema-implementation-guide)
- [GB MIR and FSCA schema implementation guide](https://assets.publishing.service.gov.uk/media/6825a453ffcd6ecfbf1ab8e6/GB_schema_implementation_guide.pdf)
- [WITHDRAWN 16/10/25 - Implementation of data requirements under the new Post-Market Surveillance regulations](/government/publications/more-implementation/implementation-of-data-requirements-under-the-new-post-marketing-surveillance-regulations)